๐ฐ Solid Tumor News
Page 5 - Solid Tumor News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Solid Tumor. Real-time updates on events, politics, business and more.
May 29, 2023
Dublin, May 29, 2023 (GLOBE NEWSWIRE) -- The "Squamous-Cell Lung Cancer in the United States, 2022-2042: Cancer Populations USA Report and Data...
May 26, 2023
Dublin, May 26, 2023 (GLOBE NEWSWIRE) -- The "Non-Squamous Non-Small-Cell Lung Cancer in the United States, 2022-2042: Cancer Populations USA Report and...
May 25, 2023
Danish early-stage biotech company InProTher has raised โฌ6M seed funding from private investors to advance its lead drug candidate IPT001.
May 17, 2023
NEW YORK, May 17, 2023 -- Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today presents clinical data... | May 17, 2023
May 17, 2023
NEW YORK, May 17, 2023 -- Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today presents clinical data... | June 12, 2023
May 3, 2023
02.05.2023 - NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) - Cellectis (the โCompanyโ) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today ... Seite 1
May 2, 2023
NEW YORK, May 02, 2023 -- Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will... | May 2, 2023
April 18, 2023
NYS Department of Health Clinical Laboratory Evaluation Program certifies Intermountain Precision Genomics Laboratory.
April 6, 2023
Erleada is available as a 240mg tablet for patients with non-metastatic castration-resistant and metastatic castration-sensitive prostate cancer.
April 3, 2023
Erleada is available as a 240mg tablet for patients with non-metastatic castration-resistant and metastatic castration-sensitive prostate cancer.